Cannabis abuse in adolescence and the risk of psychosis: A brief review of the preclinical evidence

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 52, Issue , 2014, Pages 41-44

  Rubino, T ^a   Parolaro, D ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Adolescence; Animal models; Cannabinoids; Schizophrenia like phenotype

Indexed keywords

CANNABINOID; ENDOCANNABINOID;

ADOLESCENT; ARTICLE; BRAIN MATURATION; CANNABIS ADDICTION; COGNITION; COGNITIVE DEFECT; CONNECTOME; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HYPERACTIVITY; NONHUMAN; PHENOTYPIC VARIATION; PSYCHOSIS; RISK ASSESSMENT; RISK FACTOR; SENSORY GATING; SOCIAL INTERACTION; STEREOTYPY; VULNERABLE POPULATION; ANIMAL; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; HUMAN RELATION; INHIBITION (PSYCHOLOGY); MARIJUANA ABUSE; PHYSIOLOGY; PSYCHOLOGY; SCHIZOPHRENIA; STARTLE REFLEX;

ADOLESCENT; ANIMALS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HUMANS; INHIBITION (PSYCHOLOGY); INTERPERSONAL RELATIONS; MARIJUANA ABUSE; REFLEX, STARTLE; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84899641166     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.07.020     Document Type: Article

References (38)

1. Abush H., Akirav I. Short- and long-term cognitive effects of chronic cannabinoids administration in late-adolescence rats. PLoS One 2012, 7:e31731.
2. Anticevic A., Repovs G., Krystal J.H., Barch D.M. A broken filter: prefrontal functional connectivity abnormalities in schizophrenia during working memory interference. Schizophr Res 2012, 141:8-14.
3. Bayer T.A., Falkai P., Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis". J Psychiatr Res 1999, 33:543-548.
4. Boyer P., Phillips J.L., Rousseau F.L., Ilivitsky S. Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. Brain Res Rev 2007, 54:92-112.
5. Cha Y.M., Jones K.H., Kuhn C.M., Wilson W.A., Swartzwelder H.S. Sex differences in the effects of delta9-tetrahydrocannabinol on spatial learning in adolescent and adult rats. Behav Pharmacol 2007, 18:563-569.
6. D'Souza D.C., Sewell R.A., Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009, 259:413-431.
7. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988, 31:47-59.
8. Evins A.E., Green A.I., Kane J.M., Murray R.M. The effect of marijuana use on the risk for schizophrenia. J Clin Psychiatry 2012, 73:1463-1468.
9. Giedd J.N., Blumenthal J., Jeffries N.O., Castellanos F.X., Liu H., Zijdenbos A., et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999, 2:861-863.
10. Gleason K.A., Birnbaum S.G., Shukla A., Ghose S. Susceptibility of the adolescent brain to cannabinoids: long-term hippocampal effects and relevance to schizophrenia. Transl Psychiatry 2012, 2:e199.
11. Higuera-Matas A., Botreau F., Miguéns M., Del Olmo N., Borcel E., Pérez-Alvarez L., et al. Chronic periadolescent cannabinoid treatment enhances adult hippocampal PSA-NCAM expression in male Wistar rats but only has marginal effects on anxiety, learning and memory. Pharmacol Biochem Behav 2009, 93:482-490.
12. Leweke F.M., Schneider M. Chronic pubertal cannabinoid treatment as a behavioural model for aspects of schizophrenia: effects of the atypical antipsychotic quetiapine. Int J Neuropsychopharmacol 2011, 14:43-51.
13. Llorente-Berzal A., Fuentes S., Gagliano H., López-Gallardo M., Armario A., Viveros M.P., et al. Sex-dependent effects of maternal deprivation and adolescent cannabinoid treatment on adult rat behaviour. Addict Biol 2011, 16:624-637.
14. Lodge D.J., Grace A.A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav Brain Res 2009, 204:306-312.
15. Long L.E., Chesworth R., Huang X.F., McGregor I.S., Arnold J.C., Karl T. Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol 2013, 16:163-175.
16. López-Gallardo M., López-Rodríguez A.B., Llorente-Berzal Á., Rotllant D., Mackie K., Armario A., et al. Maternal deprivation and adolescent cannabinoid exposure impact hippocampal astrocytes, CB1 receptors and brain-derived neurotrophic factor in a sexually dimorphic fashion. Neuroscience 2012, 204:90-103.
17. Malone D.T., Taylor D.A. The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behav Brain Res 2006, 166:101-109.
18. O'Shea M., Singh M.E., McGregor I.S., Mallet P.E. Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 2004, 18:502-508.
19. O'Shea M., McGregor I.S., Mallet P.E. Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. J Psychopharmacol 2006, 20:611-621.
20. O'Tuathaigh C.M., Hryniewiecka M., Behan A., Tighe O., Coughlan C., Desbonnet L., et al. Chronic adolescent exposure to δ-9-tetrahydrocannabinol in COMT mutant mice: impact on psychosis-related and other phenotypes. Neuropsychopharmacology 2010, 35:2262-2273.
21. O'Tuathaigh C.M., Clarke G., Walsh J., Desbonnet L., Petit E., O'Leary C., et al. Genetic vs. pharmacological inactivation of COMT influences cannabinoid-induced expression of schizophrenia-related phenotypes. Int J Neuropsychopharmacol 2012, 15:1331-1342.
22. Paparelli A., Di Forti M., Morrison P.D., Murray R.M. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci 2011, 5:1.
23. Paus T., Zijdenbos A., Worsley K., Collins D.L., Blumenthal J., Giedd J.N., et al. Structural maturation of neural pathways in children and adolescents: in vivo study. Science 1999, 283:1908-1911.
24. Powell C.M., Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol Psychiatry 2006, 59:1198-1207.
25. Quinn H.R., Matsumoto I., Callaghan P.D., Long L.E., Arnold J.C., Gunasekaran N., et al. Adolescent rats find repeated Delta(9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 2008, 33:1113-1126.
26. Realini N., Vigano D., Guidali C., Zamberletti E., Rubino T., Parolaro D. Chronic URB597 treatment at adulthood reverted most depressive-like symptoms induced by adolescent exposure to THC in female rats. Neuropharmacology 2011, 60:235-243.
27. Renard J., Krebs M.O., Jay T.M., Le Pen G. Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology (Berl) 2013, 225:781-790.
28. Rubino T., Realini N., Braida D., Guidi S., Capurro V., Viganò D., et al. Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 2009, 19:763-772.
29. Rubino T., Realini N., Braida D., Alberio T., Capurro V., Viganò D., et al. The depressive phenotype induced in adult female rats by adolescent exposure to THC is associated with cognitive impairment and altered neuroplasticity in the prefrontal cortex. Neurotox Res 2009, 15:291-302.
30. Schneider M., Koch M. Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003, 28:1760-1769.
31. Schneider M., Koch M. The effect of chronic peripubertal cannabinoid treatment on deficient object recognition memory in rats after neonatal mPFC lesion. Eur Neuropsychopharmacol 2007, 17:180-186.
32. Tau G.Z., Peterson B.S. Normal development of brain circuits. Neuropsychopharmacology 2010, 35:147-168.
33. van den Buuse M. Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects. Schizophr Bull 2010, 36:246-270.
34. van Os J., Kenis G., Rutten B.P. The environment and schizophrenia. Nature 2010, 468:203-212.
35. Vigano D., Guidali C., Petrosino S., Realini N., Rubino T., Di Marzo V., et al. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. Int J Neuropsychopharmacol 2009, 12:599-614.
36. Wegener N., Koch M. Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res 2009, 1253:81-91.
37. Whitford T.J., Rennie C.J., Grieve S.M., Clark C.R., Gordon E., Williams L.M. Brain maturation in adolescence: concurrent changes in neuroanatomy and neurophysiology. Hum Brain Mapp 2007, 28:228-237.
38. Zamberletti E., Prini P., Speziali S., Gabaglio M., Solinas M., Parolaro D., et al. Gender-dependent behavioral and biochemical effects of adolescent delta-9-tetrahydrocannabinol in adult maternally deprived rats. Neuroscience 2012, 204:245-257.